Highlights of 2025 in low- and intermediate-risk prostate cancer
Sun Feb 08 2026
In this episode, UROONCO PCa associate editor Prof. Claudia Kesch (DE) interviews Dr. Jochen Walz (FR) about the key highlights of 2025 in low- to intermediate-risk prostate cancer.
They discuss advances in imaging diagnostics, artificial intelligence and biomarkers, active surveillance, surgical techniques and radiotherapy, as well as what is anticipated in 2026.
Here are the links to the articles and interviews on the trials which were mentioned in this podcast:
OPTIMUM TrialPRIME TrialBARCODE1 studyNeuroSAFE PROOF trial resultsENZARAD trial For more updates on prostate cancer, please visit our educational platform UROONCO PCa.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
More
In this episode, UROONCO PCa associate editor Prof. Claudia Kesch (DE) interviews Dr. Jochen Walz (FR) about the key highlights of 2025 in low- to intermediate-risk prostate cancer. They discuss advances in imaging diagnostics, artificial intelligence and biomarkers, active surveillance, surgical techniques and radiotherapy, as well as what is anticipated in 2026. Here are the links to the articles and interviews on the trials which were mentioned in this podcast: OPTIMUM TrialPRIME TrialBARCODE1 studyNeuroSAFE PROOF trial resultsENZARAD trial For more updates on prostate cancer, please visit our educational platform UROONCO PCa. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.